The size of the Plasma Fractionation Market in North America was worth USD 7.00 billion in 2022. This value is forecasted to be growing at a CAGR of 8.3% and value USD 10.42 billion by 2027. Increasing the use of immunoglobulins in several therapeutic areas, increasing the aged population, and the rise in prevalence of rare diseases are primarily driving the growth of the North American plasma fractionation market.
Plasma Fractionation consists of the fractionation of blood into its constituent parts of red cells, white cells, and platelets suspended in plasma. The plasma is studied for deficiencies relating to blood disorders and replaced or supplemented with a cure.
Plasma, which constitutes about 55% of blood by volume, consists of several different proteins numbering into the thousands and other substances like minerals, hormones, etc. There are many therapeutic uses for the proteins present in plasma. For example, Albumin is commonly used to rejuvenate and maintain blood volume after traumatic injury, surgery, and plasma exchange.
Increasing the use of immunoglobulins, antibodies, the rising incidence of immune and bleeding disorders, the growing occurrence of Alpha-1 Antitrypsin deficiency, and the aging population prone to blood-related ailments are key factors driving the market.
However, adversarial reactions to the procedure of plasma fractionation and transfer, high costs of plasma products, and unfavorable reimbursement policies are the main constraints of market growth.
This research report on North America Plasma Fractionation Market has been segmented and sub-segmented into the following categories:
By End User:
Based on the region, the North American plasma fractionation market accounted for a significant chunk of the global share in 2020. The U.S. accounted for a considerable share in the North American market. Swift introduction of new blood-related procedures driven by the increasing incidence of blood disorders due to the growing population age drives the North American plasma fractionation market.
The U.S. Plasma Fractionation Market is estimated to occupy a significant share in the North American market during the forecast period due to technological advancements, favorable reimbursement policies, and a high standard of living that have led to increased life expectancy. The growing geriatric population in the United States is expected to drive the market because aging is considered the top risk factor for developing cardiovascular and neurological diseases in aged people. In the United States, the population age 60 and more numbered 49.2 million in 2016, representing 15.2% of the population, about one in every seven Americans. The increasing number of plasma collection centers across the United States is expected to help the market's growth. According to FDA data in the United States, there are 805 plasma donation centers. The cases of COPD are likely to increase in the United States due to substantial smoking prevalence and geriatric populations. Moreover, according to the American Academy of Allergy, Asthma & Immunology, in 2016, around 8.3% of children in the United States had asthma disease. Asthma is the most common chronic disease found in American children.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the North American plasma fractionation market profiled in the report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org